Related to NY Biotech Leaders Pursue Empire State of Mind with One-Stop Shop Proposal

• Marketing Innovations for Biotechs to Increase Revenues
  Looking outside the industry can bring breakthroughs.
  
• Supreme Court’s Decision in Matrixx v. Siracusano Calls for More Disclosure of Adverse Events to Investors
  Side effects that are not statistically significant must also be divulged.
  
• More VC But Fewer Deals Signal That Investors Are Becoming Even More Risk Averse
  While the love affair may be ending, venture capitalists are still opening up their wallets to later-stage companies.
  
• What Does It Take to Swing the IPO Window Open for Biotechs?
  Suggestions include selling at a discount at a time when there is a rising investor fan-base for social media.
  
• Biopharma Venture Funds Are Stepping Up Where VC Firms Are Stepping Out
  Such deals bring corporate giants some control in technology developers, who in turn gain the possibility of an exit through M&A.
  
• Continuing Freeze in Credit Warms Biopharma to Royalty Monetization Deals
  Industry and academia are both turning to this type of financing for cash now.
  
• Largest U.S. Biotech Clusters Faced Similar Challenges This Year as Seen Elsewhere
  California, Massachusetts, North Carolina, and Maryland have had to find ways to deal with lower funding and attract more firms.
  
• New Biotech Clusters in the U.S. Are Scrambling to Challenge Established Regions
  Various cities are trying to attract more talent and incentives to meet demands of the life science industry.
  
• Private Exchanges Emerge as an Alternative Financing Strategy
  Firms can stay private but trade their shares on these exchanges.
  
• The Academy for Medical Development & Collaboration Morphs into a Shared-Services Facilitator
  AMDeC is launching an enhanced core lab registry and vendor program to aid buyers in finding products and services.
  
• Biopharma Will Need More than New Law to Embrace Crowdfunding
  Since product development takes longer and industry has more regulation, financing alternative has yet to prove itself.
  
• Massachusetts Sees $2B Construction Boom from the Biopharma Industry
  Growth has been built on academic expertise and fueled by tax breaks.
  
• Even If Bills to Hasten Drug Approvals Pass, Investments May Remain Dry Longer than Stakeholders Claim
  Accelerated approval of any form will likely not sufficiently irrigate the valley of death.
  
• Buyout Options Gaining a Foothold in Deals Means that More than the Price Is Right
  Buyout rights are attractive to smaller firms as they offer up-front payments and a longer-term path to liquidity.
  
• Recent Flurry of New Life Science Funds Aim to Start Bridging the Valley of Death
  It remains to be seen whether these partnerships will succeed in advancing more medicines.
  
• M&A Likely to Continue Growing Along with Deal Premiums and Multiples
  Slow comeback of IPO market will keep companies looking for opportunities to be acquired.
  
• San Diego Stands as a Top U.S. Bioregion
  
  
• Biopharma Job Outlook Bleak through Mid-Decade
  Restructuring, outsourcing, and patent expirations have combined to create a tumultuous job market.
  
• NIH Taps 25 Schools to Receive Top Dollars
  Did your alma mater make the list?
  
• Top 25 Biotech Companies
  Did your company make the list?